NCT03935347 2020-01-02Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyRoswell Park Cancer InstitutePhase 2 Withdrawn